PDCD1 and neoplasm: Similarly, the TOPACIO/Keynote 162 study reported promising tumor response rates with the combination of the PARP inhibitor niraparib and the PD-1 inhibitor pembrolizumab in patients with platinum-resistant relapsed OC [96].